GENESIS: Due Diligence Service for Drugs

ERBC is proud to announce the launch of GENESIS, a new service designed to support early-phase therapeutic programs with scientific due diligence and strategic risk assessment.

GENESIS delivers a 360° analysis across key pillars of drug development — from target and pharmacology to non-clinical proof of concept, formulation, and clinical endpoints.

What GENESIS offers:

A clear picture of your program’s scientific and technical maturity
Expert insight into risk areas and key decision drivers
Strategic guidance for investment, go/no-go decisions, and prioritization
A concise, structured report to support fundraising and partnerships

Built on direct interaction with ERBC’s scientific experts, GENESIS is fast, collaborative, and fully customizable to your project.

If you are interested in seeing a sample report: